Epstein–Barr Virus: Emerging and Re-emerging Viral Infectious Diseases

The Epstein–Barr virus (EBV), also referred to as the human herpesvirus, is a herpes virus. It ranks among the most common viruses that affect people. The majority of people contract EBV at some point in their lives. EBV is most frequently transmitted by body fluids, particularly saliva. Infectious mononucleosis, usually known as mono, and other illnesses can be brought on by EBV. The majority of adults or teenagers who experience EBV infection symptoms recover in 2–4 weeks. Some individuals, however, may experience weariness for several weeks or even months. The EBV virus infects the individual and then becomes dormant. The virus may occasionally reactivate. Although symptoms are not usually the result, those with compromised immune systems are more susceptible to experience them if EBV reactivates. Because the symptoms of EBV infection are similar to those of other disorders, diagnosing that it can be difficult. Blood testing that looks for antibodies can identify EBV infection. There is currently no vaccination available to guard against EBV infection. By avoiding kissing and exchanging food, drinks, and personal objects like toothbrushes with those who have the EBV infection, one can better safeguard against EBV. EBV may potentially be involved in the development of rare cancers and other diseases, such as autoimmune disorders and schizophrenia. With reduced mortality and morbidity, significant progress has been made in therapy, but there are still certain obstacles to overcome, particularly for the most aggressive diseases. A more comprehensive solution to this public health issue would be to prevent it with EBV vaccine, but more active research is required before this objective can be achieved.